Get the Stockscreener App
17.00
0.65%
0.11
After Hours:
17.02
0.02
+0.12%
Neurogene Inc stock is traded at $17.00, with a volume of 76,899.
It is up +0.65% in the last 24 hours and down -1.62% over the past month.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.
See More
Previous Close:
$16.89
Open:
$17
24h Volume:
76,899
Relative Volume:
0.44
Market Cap:
$263.33M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+3.85%
1M Performance:
-1.62%
6M Performance:
-11.55%
1Y Performance:
-8.45%
1-Day Range:
$16.27
$17.51
1-Week Range:
$16.20
$17.95
52-Week Range:
$6.875
$37.27
Neurogene Inc Stock (NGNE) Company Profile
Name
Neurogene Inc
Sector
Industry
Phone
(877) 237-5020
Address
535 W 24TH STREET, NEW YORK
Compare NGNE vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NGNE
Neurogene Inc
|
17.00 | 261.62M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Neurogene Inc Stock (NGNE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-17-25 | Initiated | Craig Hallum | Buy |
| May-16-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jun-27-24 | Initiated | BMO Capital Markets | Outperform |
| Jun-11-24 | Initiated | Robert W. Baird | Outperform |
| Apr-29-24 | Initiated | Leerink Partners | Outperform |
| Mar-21-24 | Initiated | William Blair | Outperform |
| Jan-08-24 | Initiated | H.C. Wainwright | Buy |
| Jan-05-24 | Initiated | Stifel | Buy |
| Jan-04-24 | Initiated | TD Cowen | Outperform |
View All
Neurogene Inc Stock (NGNE) Latest News
Aug Catalysts: Is Neurogene Inc a potential multi bagger2025 Trading Volume Trends & AI Based Trade Execution Alerts - baoquankhu1.vn
Rare disease biotech Neurogene to field questions at 3 investor events - Stock Titan
Neurogene announces inducement grant under Nasdaq Listing Rule - marketscreener.com
Neurogene Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
One new Neurogene hire gets 2,820 stock options over 4 years - stocktitan.net
Aug Fed Impact: Is Walgreens Boots Alliance Inc forming a breakout patternJuly 2025 Drop Watch & Consistent Profit Trading Strategies - baoquankhu1.vn
Jobs Data: Does Neurogene Inc have a competitive edgeWeekly Gains Report & Expert-Curated Trade Recommendations - baoquankhu1.vn
Brokers Issue Forecasts for Neurogene FY2025 Earnings - MarketBeat
Neurogene (NASDAQ:NGNE) Now Covered by Analysts at Lifesci Capital - Defense World
LifeSci Capital Initiates Coverage of Neurogene (NGNE) with Outperform Recommendation - Nasdaq
Analysts Set Neurogene Inc. (NASDAQ:NGNE) Target Price at $42.50 - Defense World
Neurogene Inc. (NASDAQ:NGNE) Receives Average Recommendation of "Hold" from Analysts - MarketBeat
Aug Macro: Is Neurogene Inc stock risky to hold nowQuarterly Portfolio Report & Real-Time Stock Price Movement Reports - baoquankhu1.vn
Risk Analysis: Can Neurogene Inc outperform under higher oil pricesTrade Ideas & Reliable Momentum Entry Alerts - baoquankhu1.vn
NGNE: NGN-401 shows durable, multi-domain gains in Rett syndrome, advancing toward commercialization - TradingView
Neurogene (NASDAQ:NGNE) Given “Buy” Rating at HC Wainwright - Defense World
Fund Flows: Does EXTR stock have upside surprise potentialMarket Movers & Fast Momentum Entry Tips - baoquankhu1.vn
Market Fear: Whats the analyst consensus on Neurogene Inc2025 Market Trends & Daily Volume Surge Signals - baoquankhu1.vn
Short Covering: Whats the analyst consensus on Neurogene IncJuly 2025 WrapUp & Weekly Stock Breakout Alerts - baoquankhu1.vn
HC Wainwright & Co. Reiterates Buy Rating for NGNE with $70 Pric - GuruFocus
Neurogene doses multiple patients in Rett syndrome gene therapy trial By Investing.com - Investing.com Nigeria
Neurogene outlines 2026 milestones for NGN-401 Rett therapy - The Globe and Mail
Neurogene Inc. Reports Q3 2025 Financial Results - MSN
Stifel reiterates Buy rating on Neurogene stock, cites viable safety margin By Investing.com - Investing.com South Africa
Stifel reiterates Buy rating on Neurogene stock, cites viable safety margin - Investing.com Nigeria
Market Review: Whats the analyst consensus on Neurogene IncWeekly Trend Report & Weekly High Return Forecasts - baoquankhu1.vn
Neurogene doses multiple patients in Rett syndrome gene therapy trial - Investing.com
Neurogene Announces Recent Achievements and Anticipated 2026 Key Milestones for NGN-401, a Potential Best-in-Class Gene Therapy for Rett Syndrome - marketscreener.com
Neurogene Inc Announces Key Milestones for NGN-401 Gene Therapy - TradingView — Track All Markets
Boston Herald - FinancialContent
Neurogene Announces Positive Interim Data for NGN-401 - MSN
User | custercountychief.comNeurogene Inc.Common Stock (Nasdaq:NGNE) Stock Quote - FinancialContent
Is Neurogene Inc. stock a good choice for value investors2025 Volatility Report & Safe Capital Allocation Plans - Улправда
Is Neurogene Inc. stock gaining market shareJuly 2025 Macro Moves & Consistent Return Investment Signals - Улправда
What insider purchases suggest about Neurogene Inc. (UU8) stockJuly 2025 Retail & Safe Entry Point Identification - Улправда
Neurogene Inc. (NGNE) Stock Analysis: Uncovering a 208% Potential Upside in Biotechnology - DirectorsTalk Interviews
Will Neurogene Inc. (UU8) stock attract long term capital inflows2025 Winners & Losers & Community Verified Trade Alerts - Улправда
How Neurogene Inc. (UU8) stock correlates with oil marketsAI-Driven Market Analysis & Free Realize Exceptional Returns - Улправда
Will Neurogene Inc. stock benefit from upcoming earnings reportsStock Price Forecasts & Minimal Investment Big Returns - ulpravda.ru
What analysts say about Neurogene Inc UU8 stockStock Liquidity Analysis & Free Stock Predictions and Analysis - Early Times
Shanti Educational Initiatives Limited (539921) Announces Strategic ShiftEarly Times Newspaper Jammu - Early Times
Neurogene to Participate in the 44th Annual J.P. Morgan Healthcare Conference - New Castle News
Genetic medicines firm Neurogene opens its health conference talk online - Stock Titan
Neurogene Inc.Common Stock (NQ: NGNE - FinancialContent
Pullback Watch: Is Neurogene Inc stock a good choice for value investorsJuly 2025 Retail & AI Enhanced Trading Signals - moha.gov.vn
Breakout Move: How Applied Industrial Technologies Inc AT4 stock reacts to monetary easingTrend Reversal & Safe Swing Trade Setup Alerts - moha.gov.vn
Here's Why We're Not Too Worried About Neurogene's (NASDAQ:NGNE) Cash Burn Situation - Sahm
Craig-Hallum Initiates Coverage of Neurogene (NGNE) with Buy Recommendation - MSN
Neurogene Inc. (NASDAQ:NGNE) Receives Average Recommendation of "Hold" from Brokerages - MarketBeat
Neurogene Inc. (NASDAQ:NGNE) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat
What catalysts could drive Neurogene Inc. stock higherPortfolio Diversification Tips & Free Hedging Tactics for Volatile Markets - bollywoodhelpline.com
Neurogene Inc Stock (NGNE) Financials Data
There is no financial data for Neurogene Inc (NGNE). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):